Association of Alkaline Phosphatase with Cardiovascular Disease in Patients with Dyslipidemia: A 6-Year Retrospective Study
Authors:
- Petros Spyridonas AdamidisPAPetros Spyridonas Adamidis
- Matilda FlorentinMFMatilda Florentin
- Evangelos LiberopoulosELEvangelos Liberopoulos
- Amalia Despoina KoutsogianniAKAmalia Despoina Koutsogianni
- Georgia AnastasiouGAGeorgia Anastasiou
- George LiamisGLGeorge Liamis
- Haralampos MilionisHMHaralampos Milionis
- Fotios BarkasFBFotios Barkas
Open Access
- 15 February 2024
- journal article
- research article
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 11 (2) , 60
Abstract
Background and Aim: Serum alkaline phosphatase (ALP) activity has been associated with atherosclerotic cardiovascular disease (ASCVD). We aimed to investigate the association of ALP with ASCVD in patients with dyslipidemia. Methods: We conducted a retrospective cohort study including consecutive adults with dyslipidemia followed-up for ≥3 years (from 1999 to 2022) in the outpatient Lipid Clinic of Ioannina University General Hospital, Greece. The primary endpoint was the association between baseline ALP and incident ASCVD after adjusting for traditional risk factors (i.e., sex, age, hypertension, diabetes, smoking, and dyslipidemia), baseline ASCVD, and lipid-lowering treatment. ALP levels were stratified by tertiles as follows: low: p = 0.001). Subjects in the highest ALP tertile had the highest odds for ASCVD when compared with those in the lowest tertile (OR: 2.35; 95% CI: 1.24–4.41, p = 0.008). Conclusions: The present study indicates an association between ALP and the development of ASCVD in patients with dyslipidemia, which underscores the potential of ALP as a predictive tool or a therapeutic target in the realm of ASCVD prevention within this population.Keywords
All Related Versions
This publication has 30 references indexed in Scilit:
- Differential effect of atorvastatin and pravastatin on thoracic spine attenuation: A sub-analysis of a randomized clinical trialAtherosclerosis, 2023
- LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trialAtherosclerosis, 2021
- Apabetalone lowers serum alkaline phosphatase and improves cardiovascular risk in patients with cardiovascular diseaseAtherosclerosis, 2019
- Eotaxin Augments Calcification in Vascular Smooth Muscle CellsJournal of Cellular Biochemistry, 2016
- p‐Cresyl sulfate, a uremic toxin, causes vascular endothelial and smooth muscle cell damages by inducing oxidative stressPharmacology Research & Perspectives, 2014
- Liver enzymes and risk of cardiovascular disease in the general population: A meta-analysis of prospective cohort studiesAtherosclerosis, 2014
- Association of bone turnover markers and arterial stiffness in pre-dialysis chronic kidney disease (CKD)Bone, 2011
- Short-term reduction in bone markers with high-dose simvastatinOsteoporosis International, 2005
- Statins inhibit in vitro calcification of human vascular smooth muscle cells induced by inflammatory mediatorsJournal of Cellular Biochemistry, 2004
- Oxidative stress modulates osteoblastic differentiation of vascular and bone cellsFree Radical Biology and Medicine, 2001